Literature DB >> 33526567

How Could Antibiotics, Probiotics, and Corticoids Modify Microbiota and Its Influence in Cancer Immune Checkpoint Inhibitors: A Review.

Mara Cruellas1,2, Alfonso Yubero1,2, María Zapata1,2, Eva M Galvez3, Marta Gascón1,2, Dolores Isla1,2, Rodrigo Lastra1,2, Luis Martínez-Lostao2,4,5,6,7, Maitane Ocariz1,2, Julián Pardo2,8,9,10, Ariel Ramírez11, Andrea Sesma1,2, Irene Torres-Ramón1,2, José Ramón Paño2,12.   

Abstract

Immunotherapy has become a new paradigm in oncology, improving outcomes for several types of cancer. However, there are some aspects about its management that remain uncertain. One of the key points that needs better understanding is the interaction between immunotherapy and gut microbiome and how modulation of the microbiome might modify the efficacy of immunotherapy. Consequently, the negative impact of systemic antibiotics and corticosteroids on the efficacy of immunotherapy needs to be clarified.

Entities:  

Keywords:  antibiotics; cancer immunotherapy; corticosteroids; gut microbiota; immune checkpoint inhibitors; immunotherapy

Mesh：

Substances：

Year:  2021        PMID： 33526567      PMCID： PMC8370676          DOI： 10.1128/IAI.00665-20

Source DB:  PubMed          Journal:  Infect Immun        ISSN： 0019-9567            Impact factor:   3.441


  42 in total

1.  Impact of prior antibiotic use on the efficacy of nivolumab for non-small cell lung cancer.

Authors:  Taiki Hakozaki; Yusuke Okuma; Miwako Omori; Yukio Hosomi
Journal:  Oncol Lett       Date:  2019-01-08       Impact factor: 2.967

2.  The Human Microbiome and Checkpoint Inhibition: Potential Benefits From Antibiotic Stewardship.

Authors:  Dimitrios Farmakiotis
Journal:  Clin Infect Dis       Date:  2020-07-27       Impact factor: 9.079

3.  Immune related adverse events and response to immunotherapy: Focus on corticosteroids.

Authors:  Alice Indini; Erika Rijavec; Francesco Grossi
Journal:  Lung Cancer       Date:  2020-02-17       Impact factor: 5.705

4.  Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline.

Authors:  Julie R Brahmer; Christina Lacchetti; Bryan J Schneider; Michael B Atkins; Kelly J Brassil; Jeffrey M Caterino; Ian Chau; Marc S Ernstoff; Jennifer M Gardner; Pamela Ginex; Sigrun Hallmeyer; Jennifer Holter Chakrabarty; Natasha B Leighl; Jennifer S Mammen; David F McDermott; Aung Naing; Loretta J Nastoupil; Tanyanika Phillips; Laura D Porter; Igor Puzanov; Cristina A Reichner; Bianca D Santomasso; Carole Seigel; Alexander Spira; Maria E Suarez-Almazor; Yinghong Wang; Jeffrey S Weber; Jedd D Wolchok; John A Thompson
Journal:  J Clin Oncol       Date:  2018-02-14       Impact factor: 44.544

5.  Using corticosteroids to reshape the gut microbiome: implications for inflammatory bowel diseases.

Authors:  Edmond Y Huang; Takuya Inoue; Vanessa A Leone; Sushila Dalal; Ketrija Touw; Yunwei Wang; Mark W Musch; Betty Theriault; Kazuhide Higuchi; Sharon Donovan; Jack Gilbert; Eugene B Chang
Journal:  Inflamm Bowel Dis       Date:  2015-05       Impact factor: 5.325

6.  Antibiotic Use Does Not Appear to Influence Response to Nivolumab.

Authors:  Coureche Kaderbhai; Corentin Richard; Jean David Fumet; Anne Aarnink; Pascal Foucher; Bruno Coudert; Laure Favier; Aurélie Lagrange; Emeric Limagne; Romain Boidot; Francois Ghiringhelli
Journal:  Anticancer Res       Date:  2017-06       Impact factor: 2.480

7.  Association between antibiotic-immunotherapy exposure ratio and outcome in metastatic non small cell lung cancer.

Authors:  Giulia Galli; Tiziana Triulzi; Claudia Proto; Diego Signorelli; Martina Imbimbo; Marta Poggi; Giovanni Fucà; Monica Ganzinelli; Milena Vitali; Dario Palmieri; Anna Tessari; Filippo de Braud; Marina Chiara Garassino; Mario Paolo Colombo; Giuseppe Lo Russo
Journal:  Lung Cancer       Date:  2019-04-08       Impact factor: 5.705

8.  Antibiotics are associated with decreased progression-free survival of advanced melanoma patients treated with immune checkpoint inhibitors.

Authors:  Arielle Elkrief; Layal El Raichani; Corentin Richard; Meriem Messaoudene; Wiam Belkaid; Julie Malo; Karl Belanger; Wilson Miller; Rahima Jamal; Nathalie Letarte; Philip Wong; Bertrand Routy
Journal:  Oncoimmunology       Date:  2019-02-18       Impact factor: 8.110

Review 9.  Probiotic Bacteria: A Promising Tool in Cancer Prevention and Therapy.

Authors:  Agata Górska; Dawid Przystupski; Magdalena J Niemczura; Julita Kulbacka
Journal:  Curr Microbiol       Date:  2019-04-04       Impact factor: 2.188

10.  Early use of steroids affects immune cells and impairs immunotherapy efficacy.

Authors:  Carminia Maria Della Corte; Floriana Morgillo
Journal:  ESMO Open       Date:  2019-02-27
View more
  4 in total

1.  Impact of previous corticosteroid exposure on outcomes of patients receiving immune checkpoint inhibitors for advanced non-small cell lung cancer: a retrospective observational study.

Authors:  F Nelli; A Virtuoso; J R Giron Berrios; D Giannarelli; A Fabbri; E Marrucci; E M Ruggeri
Journal:  Cancer Chemother Pharmacol       Date:  2022-03-18       Impact factor: 3.333

2.  Special Collection on the Microbiome and Infection.

Authors:  Manuela Raffatellu; Andreas J Bäumler
Journal:  Infect Immun       Date:  2021-08-16       Impact factor: 3.441

Review 3.  Biodiversity of Gut Microbiota: Impact of Various Host and Environmental Factors.

Authors:  Haseeb Anwar; Arslan Iftikhar; Humaira Muzaffar; Ahmad Almatroudi; Khaled S Allemailem; Soha Navaid; Sana Saleem; Mohsin Khurshid
Journal:  Biomed Res Int       Date:  2021-05-12       Impact factor: 3.411

4.  A Network Comparison on Safety Profiling of Immune Checkpoint Inhibitors in Advanced Lung Cancer.

Authors:  Yi-Dan Yan; Jiu-Jie Cui; Jie Fu; Ying-Jie Su; Xiao-Yu Chen; Zhi-Chun Gu; Hou-Wen Lin
Journal:  Front Immunol       Date:  2021-12-03       Impact factor: 7.561
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.